Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, Wolchok JD, Iyer G, Bajorin DF, Callahan MK, Rosenberg JE. Teo MY, et al. J Clin Oncol. 2018 Jun 10;36(17):1685-1694. doi: 10.1200/JCO.2017.75.7740. Epub 2018 Feb 28. J Clin Oncol. 2018. PMID: 29489427 Free PMC article. Clinical Trial.
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G. Pietzak EJ, et al. Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2. Eur Urol. 2019. PMID: 30290956 Free PMC article.
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.
McHugh DJ, Funt SA, Silber D, Knezevic A, Patil S, O'Donnell D, Tsai S, Reuter VE, Sheinfeld J, Carver BS, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR. McHugh DJ, et al. Among authors: funt sa. J Clin Oncol. 2020 Apr 20;38(12):1332-1337. doi: 10.1200/JCO.19.02712. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109195 Free PMC article.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA, Jhaveri KL, Lake DE, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Wang DG, et al. Among authors: funt sa. Breast Cancer Res Treat. 2020 Aug;183(1):227-237. doi: 10.1007/s10549-020-05726-y. Epub 2020 Jun 29. Breast Cancer Res Treat. 2020. PMID: 32613539 Free PMC article.
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Sarfaty M, Whiting K, Teo MY, Lee CH, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Jungbluth AA, Al-Ahmadie H, Ostrovnaya I, Chaim J, Bajorin DF, Rosenberg JE, Iyer G, Funt SA. Sarfaty M, et al. Among authors: funt sa. Cancer Med. 2021 Feb;10(3):1074-1083. doi: 10.1002/cam4.3699. Epub 2020 Dec 31. Cancer Med. 2021. PMID: 33382520 Free PMC article. Clinical Trial.
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Teo MY, Al-Ahmadie H, Seier K, Tully C, Regazzi AM, Pietzak E, Solit DB, Tickoo S, Reuter V, Cha EK, Herr H, Donahue T, Donat SM, Dalbagni G, Bochner BH, Funt S, Iyer GV, Bajorin DF, Ostrovnaya I, Rosenberg JE. Teo MY, et al. Br J Cancer. 2021 Mar;124(7):1214-1221. doi: 10.1038/s41416-020-01244-2. Epub 2021 Jan 21. Br J Cancer. 2021. PMID: 33473164 Free PMC article. Clinical Trial.
82 results